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Abstract: The forkhead family transcriptional factor (Foxp3) is an important lineage marker for regulatory T (Treg) cells. 
Foxp3 expression is primarily restricted to CD4
+CD25
+ cell population. Recently,  an intriguing phenomenon is 
highlighted that there is a considerable amount of CD4
+CD25
Foxp3
+ T cells present in the peripheral blood of patients 
with systemic lupus erythematosus (SLE). Up to now, it is still an open question as to the nature of this cell subset. 
Following an analyses of the available phenotypic characteristics of CD4
+CD25
Foxp3
+ T cell subset along with some 
new findings in research of Treg in human SLE, we propose the hypothesis: the increased circulating CD4
+CD25
Foxp3
+ 
T cells in patients with SLE may constitute a peripheral reservoir of CD4
+CD25
+ Foxp3
+ Treg cells. Under the condition 
of autoimmune response reactivated, CD4
+CD25
Foxp3
+ T cells could be recruited to expand the Treg pool upon CD25 
regaining, for the effort to try to reverse a homeostatic imbalance shift to more aggressive expansion of autoreactive T 
cells and B cells. This hypothesis, if confirmed, would provide a new strategy for the treatment of SLE via the generation 
of therapeutic regulatory T cells. 
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INTRODUCTION 
 CD4
+CD25
+Foxp3
+ regulatory T (Treg) cells play a 
crucial role in maintaining peripheral tolerance and provide 
prevention from autoimmune disease [1]. It is well known 
that the milestone in Treg research is the discovery of the 
function of Foxp3. Mutation in the Foxp3 gene has been 
identified as the disease-causative gene in Scurfy mouse, 
which spontaneously develops severe autoimmunity, as well 
as a similar human disease called IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome) [2, 3]. Both of these diseases arise from a lack of 
functional Treg cells. Foxp3 is the key molecule not only for 
the development and function of thymus-derived, naturally 
occurring Treg (nTreg) cells but also for the induced Treg 
(iTreg) cells which are generated in the periphery. Retroviral 
transduction of the Foxp3 gene converts naïve CD4
+CD25
- T 
cells to phenotypical and functional Treg cells [4]. Such 
transduced cells display in vivo and in vitro suppressive 
activity. Naïve CD4
+ T cells can differentiate into Foxp3
+ 
Treg cells in the periphery in the presence of IL-2 and TGF-ß 
[5, 6]. Although transient up-regulation of Foxp3 expression 
has been observed in human T cells upon activation, 
conflicting data have also been published concerning the 
suppressive capacity of T cells with transient Foxp3 
expression [7-9]. 
  Foxp3 remains the specific intracellular marker for Treg 
to date. CD25 retains the conventional surface marker 
enabling easy isolation of Treg cell subset ex vivo. Foxp3  
expression  is  primarily  restricted  to  CD4
+CD25
+   cell  
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population. In addition, Foxp3 expression is also detectable 
at a low level in CD4
+CD25
– cells in mice and humans [10, 
11]. Partly because of very limited amount, CD4
+CD25
Foxp3
+ 
T cell subset attracted little attention in the past years. Very 
recently, four separate groups have reported one after 
another that there is a considerable amount of CD4
+CD25
 
Foxp3
+ T cells present in the peripheral blood of patients 
with systemic lupus erythematosus (SLE) [12-16]. The 
proportion of CD4
+CD25
Foxp3
+ T cells within CD4
+ 
lymphocytes is nearly up to 8% [16]. SLE is a disorder of 
immune regulation characterized by the breakdown of 
peripheral tolerance to self-antigens and the production of 
various autoantibodies. Many T-cell and B-cell 
abnormalities have been described [17], and these include 
the perturbation of Treg cell subset revealed in recent years 
[18]. However, the nature of CD4
+CD25
Foxp3
+ T cell 
subset and the clinical significance of their increased 
quantity in patients with SLE have little known. 
PHENOTYPE ANALYSIS OF CD4
+CD25
FOXP3
+ T 
CELL 
  By flow-cytometric analysis, several groups reported that 
CD4
+CD25
Foxp3
+ T cells in the peripheral blood from 
lupus patients expressed few level of CD127, another 
important phenotypic characteristic for Treg [13, 15, 16]. 
Furthermore, Bonelli and colleagues performed detailed 
comparative phenotypic analyses of CD4
+CD25
Foxp3
+ T 
cells and CD4
+CD25
+ Foxp3
+ Treg cells among SLE patients 
and healthy controls. A similar expression pattern was 
observed for both CD4
+CD25
Foxp3
+ T cells and 
CD4
+CD25
+ Foxp3
+ Treg cells from SLE patients concerning 
the expression of several surface and intracellular marker 
molecules that have been described to be associated with a 
Treg phenotype, such as CD62L, CD95, GITR, CTLA-4 and 
CD127. Subsequently, they sorted CD4
+CD25
CD127
 T-Cell Subset in Human SLE  The Open Rheumatology Journal, 2009, Volume 3    23 
cells from SLE patients, substituted for CD4
+CD25
Foxp3
+ 
T cells, to evaluate their regulatory function in vitro. 
Unfortunately, these cells were shown to perform partial 
regulatory activity in that they were only able to suppress 
effector T cell proliferation but not IFN- production [16]. 
  Notably, two groups described another phenotype 
characteristic that CD4
+CD25
Foxp3
+ T cell subset in SLE 
patients is CD45RO
+ in the overwhelming majority [15, 16]. 
On the other hand, this cell subset in healthy donors consists 
of more CD45RA
+ cells. This may suggest that most of the 
CD4
+CD25
Foxp3
+ T cells in the peripheral blood from 
SLE patients have undergone autoantigen stimulation and 
been in the memory CD4
+ T cell compartment. In human, it 
has been suggested that memory CD4
+ T cells may be the 
peripheral origin of adaptive CD4
+CD25
+Foxp3
+cells, also 
called iTregs [19, 20]. Both iTreg cells and nTreg cell 
constitute the CD4
+CD25
+Foxp3
+Treg pool circulating in the 
blood. A study by Vukmanovic-Stejic and colleagues 
revealed that there was extremely close T cell receptor 
(TCR) clonal homology between human CD4
+CD25
 
CD45RO
+ T cells and CD4
+CD25
+Foxp3
+ Treg cells. These 
authors proposed that iTreg, emerging at the periphery from 
the memory T cell compartment, was mainly responsible for 
the dynamic expansion of the CD4
+CD25
+Foxp3
+ Treg pool 
during an antigen-specific response [20]. Interestingly, there 
has been accumulating evidence which indicate that the 
percentages of CD4
+CD25
+Foxp3
+ Treg cells in the 
peripheral blood of SLE patients increase during their 
disease in the active stage [12, 14, 21, 22]. 
HYPOTHESIS 
  In light of these findings, we propose the hypothesis as 
follows: The increased CD4
+CD25
Foxp3
+ T cell subset in 
the peripheral blood of SLE patients may constitute a 
peripheral reservoir of CD4
+CD25
+  Foxp3
+  Treg cell 
population. Under the condition of autoimmune responses 
reactivated, CD4
+CD25
Foxp3
+ T cells could be recruited to 
expand the Treg pool upon CD25 regaining, for the effort to 
try to reverse a homeostatic imbalance shift to more 
aggressive expansion of autoreactive T cells and B cells in 
SLE. 
DISCUSSION 
  We propose this hypothesis rather than one which 
recognizes CD4
+CD25
Foxp3
+ T cells as conventional Treg 
cells, based on some new findings in research of Treg in 
human SLE and several characteristics belonged to this 
autoimmune disease itself. 
  There is a wide spectrum in human lupus ranging from 
solely involvement in skin to systemic disease. Beyond 
initial studies about Treg in human lupus, emerging data 
have revealed that the proportion of CD4
+CD25
+Foxp3
+ 
Treg cells as well as CD4
+CD25
Foxp3
+ T cells in the 
peripheral blood of lupus patients both increase and 
positively correlate with disease activity [12-16, 21, 22]. As 
for Treg function, there is also emerging evidence supporting 
that a relative deficiency of Treg function, rather than an 
intrinsic deficiency, is involved in the development of 
human lupus. This abnormality may be due to the resistant 
effect on Treg suppression direct from effector T cells, or the 
blockade effect on Treg suppression indirect from 
antigen-presenting cells [18, 21, 22]. In fact, the 
phenomenon of relative insufficiency of Treg function has 
been reported in numerous animal models [23]. The same 
trend is now emerging from human studies, in particular 
those relating to SLE patients. This scenario just provide a 
rational explanation for the increased peripheral blood 
CD4
+CD25
+Foxp3
+ Treg quantity in active lupus, which 
may be the positive feedback response to the resistant / 
blockade effect on Treg suppression. Subsequently, the 
following question is: Where do the increased circulating 
CD4
+CD25
+Foxp3
+ Treg cells origin? 
  It is known that the CD4
+CD25
+Foxp3
+ Tregs circulating 
in the blood consist of nTreg cells and iTreg cells. In SLE 
patients, nTreg apoptosis is found to be exacerbated due to 
more sensitive to Fas-mediated apoptosis [24]. The 
proliferation of limited nTreg seems unlikely sufficient for a 
bulge in the CD4
+CD25
+Foxp3
+ Treg cell pool in the active 
autoimmune response. What’s more, SLE is characterized by 
a high level of IL-6 [25]. This cytokine can interfere with the 
function of nTreg [26], and can even convert nTreg cells to 
IL-17-producing cells [27]. Both IL-2, combined with 
TGF-ß, have been suggested to enable the conversion of 
iTreg from CD4
+CD25
Foxp3
 precursors in the periphery. 
However, lymphocyte production of these two cytokines is 
shown to be decreased in SLE patients [28, 29]. Therefore, 
the CD4
+CD25
Foxp3
+ T cell population may serve as the 
main replenishment for CD4
+CD25
+Foxp3
+ iTreg population 
that could rapidly be recruited to the Treg pool upon CD25 
regaining, in order to combat the more aggressive expansion 
of autoreactive T cells and B cells during disease flare. 
Fortunately, Zelenay and his colleagues addressed this 
question in their mice model and established that 
Foxp3-expressing cells encompassed in the CD45RB
low 
CD25
 subset were the cells contributing to the pool of 
CD25
+Treg during immune activities [30]. This finding may 
further support our speculation. 
FUTURE PERSPECTIVES 
  It is still an open question as to the nature of 
CD4
+CD25
Foxp3
+ T cell subset and the reason of their 
increase in patients with SLE. More information must be 
determined before a definitive conclusion can be made. In 
particular, whether CD4
+CD25
Foxp3
+ T cells and 
CD4
+CD25
+ Foxp3
+ Treg cells in SLE patients share similar 
TCR Vß usage needs to be addressed. The role of 
CD4
+CD25
Foxp3
+ T cells and CD4
+CD25
+ Foxp3
+ Treg 
cells with respect to TCR clonal homology remains to be 
clarified. Furthermore, it must be formally established 
whether the acquisition of surface CD25 by 
CD4
+CD25
Foxp3
+ T cells from SLE patients is necessary 
for their full regulatory capacity, suppressing not only 
proliferation but also IFN- production of effector T cells. If 
this is indeed the case, this would provide another strategy 
for the generation of therapeutic regulatory T cells for the 
treatment of SLE. 
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